Examination of The Cancer Genome Atlas database revealed that Ccnd2 expression was altered (mainly amplified or upregulated) in 16 % of basal-like PAM50 breast cancers vs. altered (mainly downregulated) in 4 % of luminal A/B and 0 % in Her2+ breast cancers [24, 25]. This evidence concerns the gene CCND2 and breast cancer.